Brief: Acer Therapeutics And Relief Therapeutics Announce Issuance Of U.S. Patent 11,154,521 Covering ACER-001 Formulation
26/10/2021 13:36
Oct 26 (Reuters) - Acer Therapeutics Inc ACER.O :
* ACER THERAPEUTICS AND RELIEF THERAPEUTICS ANNOUNCE
ISSUANCE OF
U.S. PATENT 11,154,521 COVERING ACER-001 FORMULATION
* ACER THERAPEUTICS INC - NEWLY ISSUED PATENT HAS AN
EXPIRATION
DATE IN 2036
Source text for Eikon: ID:nGNX5gJ2Hg
Further company coverage: ACER.O
Recent news on Acer Therapeutics
See all newsBrief: Leading Independent Proxy Advisory Firms Iss And Glass Lewis Recommend Acer Therapeutics Shareholders Vote "For" The Proposed Merger And Related Proposals
U.S. STOCKS ON THE MOVE-UGI, SkyWest, Sage Therapeutics
Acer Therapeutics surges on Zevra buyout deal
Brief: Zevra Therapeutics To Acquire Acer Therapeutics, Expanding Its Rare Disease Portfolio And Adding Commercial Product
Swiss stocks - Factors to watch on August 31